200 related articles for article (PubMed ID: 38167806)
1. Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial.
Lin JX; Tang YH; Zheng HL; Ye K; Cai JC; Cai LS; Lin W; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Zheng CH; Li P; Huang CM
Nat Commun; 2024 Jan; 15(1):41. PubMed ID: 38167806
[TBL] [Abstract][Full Text] [Related]
2. Low-dose apatinib combined with camrelizumab and the SOX regimen in the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma (SPACE-neo): a protocol for an open-label, single-arm, clinical trial.
Pan L; Tian Y; Wang K; Tang J; Liu J; Zhang J; Wang M; Liu J; Xu H; Chen X
J Gastrointest Oncol; 2022 Dec; 13(6):3300-3313. PubMed ID: 36636043
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Camrelizumab in Combination With Nab-Paclitaxel Plus S-1 for the Treatment of Gastric Cancer With Serosal Invasion.
Lin JL; Lin JX; Lin JP; Zheng CH; Li P; Xie JW; Wang JB; Lu J; Chen QY; Huang CM
Front Immunol; 2021; 12():783243. PubMed ID: 35116023
[TBL] [Abstract][Full Text] [Related]
4. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.
Wang X; Li S; Sun Y; Li K; Shen X; Xue Y; Liang P; Li G; Chen L; Zhao Q; Li G; Fu W; Liang H; Xin H; Suo J; Fang X; Zheng Z; Xu Z; Chen H; Zhou Y; He Y; Huang H; Zhu L; Yang K; Ji J; Ye Y; Zhang Z; Li F; Wang X; Tian Y; Park S; Chen L
BMC Cancer; 2021 Jan; 21(1):20. PubMed ID: 33402102
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of camrelizumab combined with oxaliplatin and S-1 as neoadjuvant treatment in locally advanced gastric or gastroesophageal junction cancer: A phase II, single-arm study.
Zhong WJ; Lin JA; Wu CY; Wang J; Chen JX; Zheng H; Ye K
Cancer Med; 2024 Feb; 13(3):e7006. PubMed ID: 38400680
[TBL] [Abstract][Full Text] [Related]
6. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
7. Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma.
Zheng Y; Wang Z; Yan C; Yan M; Hou Z; Zheng R; Zhu Z; Li C
Ann Transl Med; 2020 Dec; 8(24):1684. PubMed ID: 33490196
[TBL] [Abstract][Full Text] [Related]
8. Oncological outcomes of sequential laparoscopic gastrectomy after treatment with camrelizumab combined with nab-paclitaxel plus S-1 for gastric cancer with serosal invasion.
Lin JL; Lin M; Lin GT; Zhong Q; Lu J; Zheng CH; Xie JW; Wang JB; Huang CM; Li P
Front Immunol; 2024; 15():1322152. PubMed ID: 38333217
[TBL] [Abstract][Full Text] [Related]
9. Apatinib plus chemotherapy versus chemotherapy alone as neoadjuvant therapy in locally advanced gastric carcinoma patients: a prospective, cohort study.
Sun Y; Fan Y; Ye Z; Dong J; Zhang L; Peng Y
Ir J Med Sci; 2023 Jun; 192(3):1033-1040. PubMed ID: 35819743
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study).
Yang Y; Zhang J; Meng H; Ling X; Wang X; Xin Y; Jiang H; Zhang L; Fang C; Liang H; Ma J; Zhu J
Int J Surg; 2024 Mar; 110(3):1430-1440. PubMed ID: 38051925
[TBL] [Abstract][Full Text] [Related]
11. The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction.
Tang Z; Wang Y; Liu D; Wang X; Xu C; Yu Y; Cui Y; Tang C; Li Q; Sun J; Zhang Q; Ji Y; Ma G; Li H; Shen Z; Shen K; Zheng R; Hou Z; Liu T; Wang J; Sun Y
Nat Commun; 2022 Nov; 13(1):6807. PubMed ID: 36357415
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant PD-1 inhibitor plus apatinib and chemotherapy versus apatinib plus chemotherapy versus chemotherapy alone in patients with locally advanced gastric cancer.
Xiong H; Li Y
Am J Cancer Res; 2023; 13(8):3559-3570. PubMed ID: 37693166
[TBL] [Abstract][Full Text] [Related]
13. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma.
Liu J; Yang Y; Liu Z; Fu X; Cai X; Li H; Zhu L; Shen Y; Zhang H; Sun Y; Chen H; Yu B; Zhang R; Shao J; Zhang M; Li Z
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338088
[TBL] [Abstract][Full Text] [Related]
14. Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Peng Z; Wei J; Wang F; Ying J; Deng Y; Gu K; Cheng Y; Yuan X; Xiao J; Tai Y; Wang L; Zou J; Zhang Y; Shen L
Clin Cancer Res; 2021 Jun; 27(11):3069-3078. PubMed ID: 33766817
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Therapy of DOF Regimen Plus Bevacizumab Can Increase Surgical Resection Ratein Locally Advanced Gastric Cancer: A Randomized, Controlled Study.
Ma J; Yao S; Li XS; Kang HR; Yao FF; Du N
Medicine (Baltimore); 2015 Oct; 94(42):e1489. PubMed ID: 26496252
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Safety of Apatinib Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer: A Nonrandomized Controlled Trial.
Lin JX; Xu YC; Lin W; Xue FQ; Ye JX; Zang WD; Cai LS; You J; Xu JH; Cai JC; Tang YH; Xie JW; Li P; Zheng CH; Huang CM
JAMA Netw Open; 2021 Jul; 4(7):e2116240. PubMed ID: 34241629
[TBL] [Abstract][Full Text] [Related]
17. Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 Study).
Yang Y; Zhu L; Cheng Y; Liu Z; Cai X; Shao J; Zhang M; Liu J; Sun Y; Li Y; Yi J; Yu B; Jiang H; Chen H; Yang H; Tan L; Li Z
BMC Cancer; 2022 May; 22(1):506. PubMed ID: 35524205
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant PD-1 inhibitor and apatinib combined with S-1 plus oxaliplatin for locally advanced gastric cancer patients: a multicentered, prospective, cohort study.
Xu C; Xie X; Kang N; Jiang H
J Cancer Res Clin Oncol; 2023 Jul; 149(7):4091-4099. PubMed ID: 36042044
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients With Resectable NSCLC: A Phase 2 Clinical Trial.
Zhao J; Zhao L; Guo W; Wang S; Tao X; Li L; Mao Y; Tan F; Gao Y; Wu N; Ying J; Xue Q; Li N; Gao S; He J
J Thorac Oncol; 2023 Jun; 18(6):780-791. PubMed ID: 36870519
[TBL] [Abstract][Full Text] [Related]
20. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
